NM001
Cystic Fibrosis
Phase 2Active
Key Facts
About NovaBiotics
NovaBiotics is an innovative, privately-held biotech group with a bifurcated strategy. Its advanced Pharma pipeline, featuring host-directed anti-infectives like NM001 and NM002, targets significant unmet needs in cystic fibrosis, respiratory infections, and mycobacterial diseases like TB. Concurrently, its commercial Consumer Health arm generates early revenue through Tinexyl PRO, a professional-grade nail health product, providing a non-dilutive funding stream and market validation for its platform. The company is led by founder and CEO Dr. Deborah O'Neil and maintains strategic collaborations with academic and commercial partners.
View full company profileTherapeutic Areas
Other Cystic Fibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| CB-280 | Calithera Biosciences | Preclinical/Phase 1 |
| Ensifentrine | Verona Pharma | Phase 2 |
| ALTA Drug Series | Alteron Therapeutics | Preclinical |
| ColiFin® | Spexis | Marketed (EU) |
| Cystic fibrosis (CRISPR) | GeneToBe | Discovery |
| Cystic fibrosis (undisclosed) | GeneToBe | Early Discovery |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| Targeted Lung Delivery | Nanite | Pre-clinical |
| CFTR 100+ Panel | Agena Bioscience | Commercial |
| RIG-301 CFTR | RIGImmune | Pre-clinical |
| CBN-101 | Carbon Biosciences | Preclinical |
| RESP® Biosensor Evaluation (with Rutgers Health) | Strados Labs | Research Study |